News about Drug Discovery & Development

Advanz Pharma and Alvotech announce EMA acceptance of application for proposed Xolair biosimilar AVT23

Omalizumab, the active ingredient in Xolair, is a prescription biologic used to improve the control of severe persistent allergic asthma in patients aged six years and older when blood tests confirm immunoglobulin E (IgE) involvement.

Drug Discovery & Development | 07/10/2025 | By Darshana |  188

Illumina Launches BioInsight to Drive Multiomic Data and AI-Powered Drug Discovery

Illumina, Inc., a global leader in genomics and precision health, has announced the launch of BioInsight, a new business designed to meet the growing demand for deeper biological insights driven by large-scale multiomic data.

Drug Discovery & Development | 04/10/2025 | By Darshana |  553

Bristol Myers and Takeda Join AI Consortium to Accelerate Drug Discovery

Bristol Myers Squibb and Takeda Pharmaceuticals have agreed to collaborate in a new AI-driven drug discovery initiative, pooling proprietary molecular structure datasets to train an advanced AI model known as OpenFold3.

Drug Discovery & Development | 01/10/2025 | By Darshana |  590

Concept Life Sciences Unveils Major Expansion of UK Drug Discovery Facilities

Concept Life Sciences, a multi-disciplined contract research organisation, has officially opened its newly expanded integrated drug discovery facilities at its Chapel-en-le-Frith headquarters, establishing one of the UK’s largest drug discovery research sites.

Drug Discovery & Development | 30/09/2025 | By Darshana |  141

Akums Highlights Lacosamide's Versatility in Epilepsy Management

Akums Drugs & Pharmaceuticals reaffirmed lacosamide, a well-established antiepileptic drug (AED), as a versatile and effective option for patients with epilepsy across age groups and clinical settings.

Drug Discovery & Development | 22/09/2025 | By Dineshwori |  166

Orforglipron by Lily Shows Significant Weight Loss and Cardiometabolic Gains in ATTAIN-1 Results

Orforglipron by Eli Lily demonstrated significant improvements across key cardiometabolic risk factors, supporting its potential as a treatment option for millions living with obesity.

Drug Discovery & Development | 18/09/2025 | By Dineshwori |  231

CDSCO Clarifies Regulatory Pathway: Cocrystals of Approved Drugs to Be Treated as New Drugs

The Central Drugs Standard Control Organisation (CDSCO) has issued a clarification stating that cocrystals of already approved active substances will be treated as new drugs under Indian regulations.

Drug Discovery & Development | 17/09/2025 | By Darshana |  232

Roche Pharma India Expands AIR Initiative to Boost Clinical Trial Capacity

Roche Pharma India has successfully completed the first phase of its Advanced Inclusive Research (AIR) Site Alliance programme. The initiative engaged 10 leading government hospitals across the country and trained nearly 400 professionals—including investigators, ethics committee members, and support staff—in global Good Clinical Practice standard.

Drug Discovery & Development | 16/09/2025 | By Darshana |  178

Monte Rosa Therapeutics Partners with Novartis on Degraders for Immune Diseases

Monte Rosa to receive an upfront payment of USD 120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory and sales milestones, as well as tiered royalties on global net sales.

Drug Discovery & Development | 16/09/2025 | By Dineshwori |  244

ANVISA Approves Concept Medical's MagicTouch SCB for CAD in Brazil

The approval enables commercial sales in Brazil, strengthening Concept Medical’s global footprint and advancing its mission to deliver safer and more effective treatment alternatives. The company is also undergoing ANVISA’s approval process for its wider DCB and DES portfolio, building on its robust clinical trial foundation.

Drug Discovery & Development | 16/09/2025 | By Dineshwori |  271